Oramed Pharmaceuticals Inc Overview
Industry: Biotechnology
Sector: Healthcare
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Oramed Pharmaceuticals Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Oramed Pharmaceuticals Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Oramed Pharmaceuticals Inc Competitors
Oramed Pharmaceuticals Inc operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans